DK3334500T3 - Multiligand-lægemiddelskonjugater og anvendelser deraf - Google Patents

Multiligand-lægemiddelskonjugater og anvendelser deraf Download PDF

Info

Publication number
DK3334500T3
DK3334500T3 DK16834681.5T DK16834681T DK3334500T3 DK 3334500 T3 DK3334500 T3 DK 3334500T3 DK 16834681 T DK16834681 T DK 16834681T DK 3334500 T3 DK3334500 T3 DK 3334500T3
Authority
DK
Denmark
Prior art keywords
multiligand
conjugates
medicines
multiligand medicines
medicines conjugates
Prior art date
Application number
DK16834681.5T
Other languages
Danish (da)
English (en)
Inventor
Baohua Robert Huang
Jian Dai
Zhongbo Wang
Xueyuan Xie
Xiaodong Liu
Xinli Hu
Original Assignee
Coherent Biopharma I Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201510489556.6A external-priority patent/CN106466485B/zh
Priority claimed from CN201510489560.2A external-priority patent/CN106466484B/zh
Application filed by Coherent Biopharma I Ltd filed Critical Coherent Biopharma I Ltd
Application granted granted Critical
Publication of DK3334500T3 publication Critical patent/DK3334500T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK16834681.5T 2015-08-11 2016-08-11 Multiligand-lægemiddelskonjugater og anvendelser deraf DK3334500T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510489556.6A CN106466485B (zh) 2015-08-11 2015-08-11 一种具有细胞内吞介导功能的靶向配体-药物偶联体
CN201510489560.2A CN106466484B (zh) 2015-08-11 2015-08-11 一种具有细胞内吞介导功能的多靶向配体-药物偶联体
PCT/CN2016/094704 WO2017025057A1 (en) 2015-08-11 2016-08-11 Multi-ligand drug conjugates and uses thereof

Publications (1)

Publication Number Publication Date
DK3334500T3 true DK3334500T3 (da) 2021-06-21

Family

ID=57983917

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16834681.5T DK3334500T3 (da) 2015-08-11 2016-08-11 Multiligand-lægemiddelskonjugater og anvendelser deraf

Country Status (13)

Country Link
US (2) US11571480B2 (enExample)
EP (1) EP3334500B1 (enExample)
JP (3) JP6772199B2 (enExample)
KR (2) KR102301596B1 (enExample)
CN (3) CN111617250B (enExample)
AU (2) AU2016305703B2 (enExample)
CA (1) CA2987322C (enExample)
DK (1) DK3334500T3 (enExample)
ES (1) ES2877409T3 (enExample)
MX (1) MX381031B (enExample)
RU (1) RU2722449C2 (enExample)
WO (1) WO2017025057A1 (enExample)
ZA (1) ZA201707464B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5836940B2 (ja) 2009-06-26 2015-12-24 ソリシメド・バイオファーマ・インコーポレーテッド ソリシジン由来ペプチドならびにｔｒｐｖ−６がんの検出および薬剤送達のための方法
CA2987322C (en) * 2015-08-11 2020-02-11 Coherent Biopharma Multi-ligand drug conjugates and uses thereof
EP3716991A4 (en) * 2017-12-01 2021-09-08 Soricimed Biopharma Inc. TRPV6 INHIBITORS AND COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
EP3720842A4 (en) 2017-12-06 2021-11-03 Ontario Institute For Cancer Research ACYLHYDRAZONE LINKERS, METHODS, AND USES THEREOF
WO2019119141A1 (en) 2017-12-22 2019-06-27 Ontario Institute For Cancer Research (Oicr) Heterocyclic acyl hydrazone linkers, methods and uses thereof
WO2019134018A1 (en) * 2018-01-05 2019-07-11 Telethon Kids Institute Vaccine conjugates and uses thereof
JP7546574B2 (ja) * 2019-01-30 2024-09-06 コヒレント バイオファーマ （スーチョウ），リミテッド 二重リガンド薬物コンジュゲート及びその使用
CA3147895A1 (en) * 2019-07-22 2021-01-28 Purdue Research Foundation Multivalent fibroblast-targeted agents and methods of use
EP4047098A4 (en) * 2019-08-20 2023-06-07 EGI Tech (Shen Zhen) Co., Limited PROCEDURE FOR SEQUENCING POLYNUCLEOTIDS BASED ON OPTICAL SIGNAL DYNAMICS OF A LUMINESCENT LABEL AND SECONDARY LUMINESCENT SIGNAL
WO2021163701A1 (en) * 2020-02-13 2021-08-19 Escape Therapeutics, Inc. Melanoma therapeutics
EP4274595A4 (en) * 2021-01-07 2026-01-21 Purdue Research Foundation FOLATE RECEPTOR-TARGETED CONJUGATES, COMPOSITIONS AND ADMINISTRATION TO THE CENTRAL NERVOUS SYSTEM
TW202317199A (zh) * 2021-06-25 2023-05-01 大陸商同宜醫藥（蘇州）有限公司 配體藥物偶聯物及其應用
CN116059392B (zh) * 2021-09-03 2025-02-28 同宜医药（苏州）有限公司 配体偶联物及其应用
AU2022344391B2 (en) * 2021-09-08 2026-02-05 Coherent Biopharma (Suzhou) Limited Pharmaceutical preparation, preparation method therefor and use thereof
WO2023066251A1 (zh) * 2021-10-19 2023-04-27 同宜医药（苏州）有限公司 偶联体药物制剂及其制备方法和用途
CN116196408B (zh) * 2021-12-30 2026-01-06 思格(苏州)生物科技有限公司 一种新型免疫佐剂及其制备方法和应用
TW202404643A (zh) * 2022-04-20 2024-02-01 大陸商同宜醫藥（蘇州）有限公司 化合物及用途
WO2024099387A1 (zh) * 2022-11-09 2024-05-16 同宜医药（苏州）有限公司 通过施用配体-药物偶联体治疗癌症
CN120813385A (zh) * 2023-03-23 2025-10-17 同宜医药（苏州）有限公司 通过施用配体-药物偶联体治疗卵巢癌
CN121001746A (zh) * 2023-04-26 2025-11-21 同宜医药（苏州）有限公司 一种配体-药物偶联体在治疗癌症中的用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093382A (en) * 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
AU2002337954C1 (en) * 2001-10-22 2008-10-23 The Scripps Research Institute Integrin targeting compounds
WO2003072754A2 (en) * 2002-02-27 2003-09-04 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
GB0209893D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
US7119168B2 (en) * 2002-11-18 2006-10-10 Bioprospecting Nb Inc. Paralytic peptide for use in neuromuscular therapy
JP5008981B2 (ja) 2003-12-05 2012-08-22 アロジーン， インコーポレイテッド ポリリンゴ酸ベースの多機能性薬物送達システム
US20100166654A1 (en) 2004-12-03 2010-07-01 The Uab Research Foundation Single-Drug Multi-Ligand Conjugates for Targeted Drug Delivery
RU2470668C2 (ru) 2005-08-19 2012-12-27 Эндосайт, Инк. Конъюгаты лиганда с несколькими лекарственными средствами
EA016577B1 (ru) 2005-09-26 2012-06-29 Медарекс, Инк. Конъюгаты антитело-лекарство и их применение
MX2009002855A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Profarmacos polimericos dirigidos que contienen enlazadores multifuncionales.
US20080181852A1 (en) 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
CN101224306B (zh) 2008-02-20 2011-04-20 中山大学 叶酸-多肽复合物介导的靶向抗肿瘤前体药物及其制备方法
CN102231951A (zh) * 2008-11-17 2011-11-02 安龙制药公司 用于核酸传递系统的可释放的偶联物
CN102282168A (zh) * 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
WO2012019121A2 (en) * 2010-08-06 2012-02-09 Board Of Trustees Of The University Of Illinois Multiplexed supramolecular assemblies for non-viral delivery of genetic material
HUE052285T2 (hu) 2011-06-06 2021-04-28 Starpharma Pty Ltd Makromolekulák
CN104302408B (zh) 2012-02-27 2016-12-14 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
CN103372199B (zh) * 2012-04-16 2015-12-16 广州暨南大学医药生物技术研究开发中心 一种预防和治疗神经退行性疾病的新型脑部靶向制剂
US9545449B2 (en) * 2012-05-11 2017-01-17 Advanced Proteone Therapeutics Inc. Site-specific labeling and targeted delivery of proteins for the treatment of cancer
GB201211309D0 (en) 2012-06-26 2012-08-08 Fujifilm Mfg Europe Bv Process for preparing membranes
AU2013288932A1 (en) 2012-07-09 2014-12-11 Genentech, Inc. Immunoconjugates comprising anti - CD79b antibodies
PL2872157T3 (pl) * 2012-07-12 2020-07-13 Hangzhou Dac Biotech Co., Ltd Koniugaty wiążących komórkę cząsteczek ze środkami cytotoksycznymi
WO2014089209A2 (en) 2012-12-04 2014-06-12 Abbvie, Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins
US10253099B2 (en) 2012-12-05 2019-04-09 Ruprecht-Karls-Universität Heidelberg Conjugates of proteins and multivalent cell-penetrating peptides and their uses
MX2015013163A (es) * 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
AU2014337317A1 (en) 2013-10-15 2016-09-15 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
CN104784699B (zh) * 2014-01-20 2019-05-03 博瑞生物医药（苏州）股份有限公司 叶酸受体结合配体-药物偶联物
EP3164420A4 (en) * 2014-06-30 2018-05-23 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
CN104667292B (zh) * 2015-02-02 2017-09-05 北京大学 一种还原响应型药物偶联物纳米粒的制备及其应用
JP6987641B2 (ja) * 2015-05-12 2022-01-05 ブリンクバイオ インコーポレイテッド シリコン系薬物複合体及びその使用方法
CA2987322C (en) * 2015-08-11 2020-02-11 Coherent Biopharma Multi-ligand drug conjugates and uses thereof
JP2020164335A (ja) * 2019-03-28 2020-10-08 イビデン株式会社 ハニカム構造体

Also Published As

Publication number Publication date
JP7573401B2 (ja) 2024-10-25
AU2019240611A1 (en) 2019-10-17
HK1250634A1 (zh) 2019-01-11
JP6772199B2 (ja) 2020-10-21
KR102301596B1 (ko) 2021-09-14
CN108135881B (zh) 2020-11-13
MX381031B (es) 2025-03-12
ZA201707464B (en) 2021-05-26
CN111617250B (zh) 2022-07-01
KR20200071152A (ko) 2020-06-18
EP3334500A1 (en) 2018-06-20
ES2877409T3 (es) 2021-11-16
CN108135881A (zh) 2018-06-08
US20240100175A1 (en) 2024-03-28
JP2018529632A (ja) 2018-10-11
AU2016305703A1 (en) 2017-11-23
RU2018104266A3 (enExample) 2019-09-12
CN111617250A (zh) 2020-09-04
US11571480B2 (en) 2023-02-07
MX2018001723A (es) 2018-05-17
RU2722449C2 (ru) 2020-06-01
AU2019240611B2 (en) 2021-09-09
KR102464778B1 (ko) 2022-11-07
US20180200377A1 (en) 2018-07-19
JP2021006549A (ja) 2021-01-21
AU2016305703B2 (en) 2019-07-25
EP3334500B1 (en) 2021-04-07
KR20180033513A (ko) 2018-04-03
CA2987322A1 (en) 2017-02-16
EP3334500A4 (en) 2019-04-03
CN112263683A (zh) 2021-01-26
RU2018104266A (ru) 2019-09-12
WO2017025057A1 (en) 2017-02-16
CA2987322C (en) 2020-02-11
JP2023025151A (ja) 2023-02-21

Similar Documents

Publication Publication Date Title
IL290457A (en) Antibodies and their conjugates
ZA202007918B (en) Anti-cd123 antibodies and conjugates and derivatives thereof
IL265309A (en) Bispecific antibodies against MUC16 and CD3 and drug conjugates against MUC16
DK3458479T3 (da) Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater
IL258248A (en) Attraction Oligonucleotide Conjugates and Their Uses
DK3354282T3 (da) Glycan-terapeutiske midler og relaterede fremgangsmåder deraf
DK3592393T3 (da) Frigørbare konjugater
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3380124T3 (da) Konjugater omfattende selv-immolative grupper og fremgangsmåder relateret dertil
DK3270965T3 (da) Cd48-antistoffer og konjugater deraf
DK3307274T3 (da) Anti-cd123-antistoffer og konjugater deraf
DK3102244T3 (da) Antistoflægemiddelkonjugater og immuntoksiner
LT3137114T (lt) Anti-ptk7 antikūnų ir vaistų konjugatai
ZA201707464B (en) Multi-ligand drug conjugates and uses thereof
DK3229838T3 (da) Anti-C10orf54-antistoffer og anvendelser deraf
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3402821T3 (da) Psma-bindende antistof og anvendelser deraf
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
EP3355931C0 (en) PROTEIN CONJUGATES
EP3370771A4 (en) ANTI-CD3-FOLAT-CONJUGATES AND ITS USES
DK3373937T3 (da) Anti-cd22-antistof-maytansin-konjugater og fremgangsmåder til anvendelse deraf
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf
DK3388085T3 (da) Farmaceutisk sammensætning og anvendelser deraf
DK3229843T3 (da) Farmaceutisk sammensætning, præparat og anvendelser deraf